Tesofensine (NS2330) is a triple reuptake inhibitor, meaning it blocks the reabsorption of three key neurotransmitters—serotonin, norepinephrine, and dopamine—in the brain. This increases their levels, providing therapeutic benefits across various regions of the brain where these neurotransmitters play important roles. Tesofensine has been explored in clinical trials for its potential use in medical weight loss.
How Does Tesofensine Work?
Tesofensine enhances levels of dopamine, norepinephrine, and serotonin, each of which plays a vital role in the brain’s functioning:
- Dopamine helps regulate mood, motor function, cognition, and reward-driven behaviors.
- Norepinephrine boosts muscle and heart contractions to maintain optimal body function.
- Serotonin regulates mood, memory, sleep, and appetite.
Chemical Structure of Tesofensine
Tesofensine is a complex pharmaceutical compound, consisting of carbon, hydrogen, oxygen, and nitrogen atoms arranged in a specific molecular structure.
Research and Clinical Trials on Tesofensine
A. Promotes Weight Loss
Tesofensine is widely recognized for its weight loss potential, largely due to its effect on dopamine levels. Dopamine helps regulate appetite, metabolism, and motivation, so increasing its levels can suppress appetite and enhance calorie burning. Clinical studies support its role in weight loss:
- Phase III trials, including the 2018 Viking study, showed significant weight reductions in obese participants, with low incidences of adverse events.
- Phase IIb trials (TIPO-1) showed that patients lost an average of 12.8 kg at the highest dose, with improvements in fat oxidation and no significant blood pressure changes.
- Additional studies have shown that tesofensine can induce appetite suppression, increase satiety, and lead to substantial weight loss, even when combined with a healthy lifestyle.
B. Improves Cognitive Health
Tesofensine may also support cognitive function by boosting cholinergic neurotransmission, which is important for learning, memory, and thinking. This has led researchers to explore its potential use in treating Alzheimer’s and Parkinson’s disease:
- Small clinical trials have shown significant cognitive improvements in patients with mild Alzheimer’s.
- Animal studies indicate that tesofensine reduces amyloid beta concentrations, a key factor in Alzheimer’s.
C. Enhances Mood
Tesofensine has been shown to improve mood by increasing levels of brain-derived neurotrophic factor (BDNF) and boosting neurotransmitters involved in mood regulation, such as serotonin, dopamine, and norepinephrine. This effect may help alleviate symptoms of depression and anxiety.
D. Improves Blood Sugar Levels
By promoting weight loss, tesofensine may improve insulin sensitivity and help lower blood sugar levels. Research supports its ability to reduce blood sugar and improve quality of life for obese individuals.
E. Increases Energy Levels
Tesofensine increases energy by enhancing neurotransmitter activity, particularly dopamine and norepinephrine, which regulate motivation and drive. This can lead to increased physical activity and higher energy expenditure.
F. Treats Sexual Dysfunction
Tesofensine’s ability to boost dopamine levels can help improve sexual function, particularly in individuals with depression-related sexual dysfunction. It may help restore sexual desire and performance.
G. Addresses Eating Disorders
Tesofensine has shown promise in treating eating disorders like binge eating. Its appetite-suppressing effects help reduce the desire to overeat, and its antidepressant properties may also play a role in managing the emotional triggers behind these conditions.
H. Treats ADHD
Studies suggest tesofensine may be effective in treating Attention-Deficit/Hyperactivity Disorder (ADHD) by increasing the levels of dopamine and serotonin, neurotransmitters often deficient in individuals with ADHD.
I. Improves Sleep Quality
By increasing serotonin levels, tesofensine may help improve sleep quality, particularly in individuals with serotonin deficiencies linked to insomnia and other sleep disorders.
J. Fights Alcohol Addiction
Tesofensine may reduce alcohol consumption by boosting dopamine levels, which are often low in individuals with alcohol addiction. Animal studies show reduced alcohol intake without affecting food or water consumption.
Side Effects of Tesofensine
While tesofensine is generally well-tolerated, some individuals may experience side effects, although these are rare. Reported side effects include:
- Constipation
- Diarrhea
- Dry mouth
- Headache
- Increased blood pressure
- Increased heart rate
- Insomnia
- Nausea
Despite these potential side effects, tesofensine’s benefits in weight loss and other therapeutic areas continue to make it a promising candidate for various health conditions.
References
- Mahapatra A. Overeating, Obesity, and Dopamine Receptors. ACS Chemical Neuroscience. 2010;1(5):346-347. doi:10.1021/cn100044y.
- Blum K, Thanos PK, Gold MS. Dopamine and glucose, obesity, and reward deficiency syndrome. Frontiers in Psychology. 2014;5:919. doi:10.33329/fpsyg.2014.00919.
- Karlsson HK, Tuominen L, Tuulari JJ. Obesity is associated with decreased μ-opioid but unaltered dopamine D2 receptor availability in the brain. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015; 35(9):3959-65.
- Wang GJ, Volkow ND, Logan J. Brain dopamine and obesity. Lancet (London, England). 2001; 357(9253):354-7.
- Benton D, Young HA. A meta-analysis of the relationship between brain dopamine receptors and obesity: a matter of changes in behavior rather than food addiction? International Journal of Obesity (2005). 2016;40(Suppl 1):S12-S21. doi:10.10332/ijo.2016.9.
- Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 20032; 372(9653):1906-1913.
- Doggrell SA. Tesofensine–a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 20032;372:1906-13. Expert opinion on investigational drugs. 2009; 132(7):1043-6.
- Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A. The effect of tesofensine on appetite sensations. Obesity (Silver Spring, Md.). 2012; 20(3):553-61.
- Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current opinion in investigational drugs (London, England : 2000). 2009; 10(10):1105-16.
- Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease. Obesity (Silver Spring, Md.). 20032; 16(6):1362-9.
- Appel L, Bergström M, Buus Lassen J, Långström B. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2014; 24(2):251-61.
- Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology, biochemistry, and behavior. 2013; 110:265-71.
